Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 406 to 420 of 2579 results for methods

  1. Inebilizumab for treating immunoglobulin G4-related disease [TSID12107]

    Awaiting development Reference number: GID-TA11665 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Linvoseltamab for treating relapsed or refractory multiple myeloma after 3 or more treatments [ID6609]

    Awaiting development Reference number: GID-TA11052 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Efzimfotase alfa for treating hypophosphatasia [ID6633]

    Awaiting development Reference number: GID-TA11838 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Tucatinib with pertuzumab and trastuzumab for maintenance treatment of HER2-positive unresectable advanced breast cancer after induction chemotherapy [ID6402]

    Awaiting development Reference number: GID-TA11487 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Trastuzumab deruxtecan for neoadjuvant treatment of HER2-positive early breast cancer [ID6620]

    Awaiting development Reference number: GID-TA11403 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Cabozantinib with atezolizumab for treating hormone-relapsed metastatic prostate cancer after 1 hormonal treatment [ID6387]

    Awaiting development Reference number: GID-TA11438 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Elinzanetant for treating vasomotor symptoms associated with menopause [ID6359]

    Awaiting development Reference number: GID-TA11428 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. PLX-PAD for treating muscle injury after arthroplasty for hip fracture in people 60 to 90 years [ID3989]

    Awaiting development Reference number: GID-TA10885 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Sonesitatug vedotin for previously treated metastatic claudin 18.2-positive gastric or gastro-oesophageal junction adenocarcinomar [ID6669]

    Awaiting development Reference number: GID-TA11879 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Aficamten for treating symptomatic non-obstructive hypertrophic cardiomyopathy [ID6668]

    Awaiting development Reference number: GID-TA11877 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Retatrutide for managing overweight and obesity [ID6644]

    Awaiting development Reference number: GID-TA11845 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Deucravacitinib for treating active psoriatic arthritis [TSID11981]

    Awaiting development Reference number: GID-TA11510 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Eplontersen for treating transthyretin-related amyloidosis cardiomyopathy [TSID12015]

    Awaiting development Reference number: GID-TA11551 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Doxecitine–doxribtimine for treating thymidine kinase 2 deficiency in people of any age who had symptoms before 13 years [TSID12046]

    Awaiting development Reference number: GID-TA11632 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Imetelstat for treating intermediate-2 or high-risk relapsed or refractory myelofibrosis after a JAK inhibitor [TSID8376]

    Awaiting development Reference number: GID-TA11608 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development